Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring
Por:
Petersen, ME, Flores-Aguilar, L, Head, E, Montoliu-Gaya, L, Strydom, A, Pape, SE, Fortea, J, Ashton, NJ, Udeh-Momoh, C, O'Bryant, SE, German, D, Despa, F, Mapstone, M, Zetterberg, H
Publicada:
1 ene 2025
Ahead of Print:
1 nov 2024
Resumen:
Blood-based biomarkers continue to be explored for disease detection, monitoring of progression, and therapeutic outcomes as the diagnostic determination of Alzheimer's Disease in Down Syndrome (DS-AD) remains challenging in clinical settings. This perspective highlights the current status of this effort. Overall, amyloid (A), tau (T), and neurodegeneration (AT[N]) blood-based biomarkers have been shown to increase with disease pathology for individuals with DS. Phosphorylated tau biomarkers (p-tau217, p-tau181) have been consistently shown to track disease progression for DS-AD and are likely good candidates for use in clinical settings. Biomarkers of inflammation (glial fibrillary acidic protein) also show promise; however, additional work is needed. Findings from stability work of blood-based biomarkers conducted among non-DS also support the potential longitudinal utility of biomarkers such as neurofilament light chain and p-tau181 in DS. Gaps in our knowledge are highlighted, and a potential role for sex differences in biomarker outcomes is noted, along with recommendations for determining the appropriate context of use when translating biomarkers into clinical applications.
Filiaciones:
Petersen, ME:
Univ North Texas, Hlth Sci Ctr, Dept Family Med, Ft Worth, TX USA
Univ North Texas, Hlth Sci Ctr, Inst Translat Res, Ft Worth, TX USA
Flores-Aguilar, L:
Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA USA
Head, E:
Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA USA
Montoliu-Gaya, L:
Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden
Strydom, A:
Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Forens & Neurodev Sci, London, England
Pape, SE:
Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Forens & Neurodev Sci, London, England
Fortea, J:
Hosp Santa Creu & Sant Pau, Inst Invest Biomed St Pau IIB St Pau, Barcelona, Spain
Ctr Biomed Invest Network Neurodegenerat Dis CIBE, Madrid, Spain
Fundacio Catalana Sindrome, Barcelona Med Ctr, Barcelona, Spain
Ashton, NJ:
Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden
Kings Coll London, South London & Maudsley NHS Fdn Trust, Inst Psychiat Psychol & Neurosci, Maurice Wohl Inst Clin Neurosci Inst, London, England
Dementia South London & Maudsley NHS Fdn, NIHR Biomed Res Ctr Mental Hlth & Biomed Res Unit, London, England
Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway
Udeh-Momoh, C:
Wake Forest Univ, Sch Med, Dept Epidemiol & Prevent, Publ Hlth Sci, Winston Salem, NC USA
Aga Khan Univ, Brain & Mind Inst, Nairobi, Kenya
O'Bryant, SE:
Univ North Texas, Hlth Sci Ctr, Dept Family Med, Ft Worth, TX USA
Univ North Texas, Hlth Sci Ctr, Inst Translat Res, Ft Worth, TX USA
German, D:
Univ Texas Southwestern Med Ctr, Dept Psychiat, Dallas, TX USA
Univ Texas Southwestern Med Ctr, ODonnell Brain Inst, Dallas, TX USA
Despa, F:
Univ Kentucky, Dept Pharmacol & Nutr Sci, Lexington, KY USA
Univ Kentucky, Dept Immunol, Lexington, KY USA
Mapstone, M:
Univ Calif Irvine, Dept Neurol, Irvine, CA USA
Zetterberg, H:
Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden
Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden
UCL, Inst Neurol, Dept Neurodegenerat Dis, London, England
UCL, UK Dementia Res Inst, London, England
Hong Kong Ctr Neurodegenerat Dis, Hong Kong, Peoples R China
Univ Wisconsin Madison, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA
Green Submitted, hybrid
|